Across TCGA pan-cancer cohorts, CENATAC Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CENATAC data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in brain lower grade glioma (LGG), where higher CENATAC Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CENATAC expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

LGG, SCLC, and PRAD are the cancer types where CENATAC Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LGG	OS	Median	All	0.128	0.811	<.001	12	view →
SCLC	OS	Median	All	0.082	0.822	<.001	12	view →
PRAD	DFS	Median	All	0.118	0.886	<.001	6	view →
BLCA	DFS	Median	II,III,IV	1.000	0.329	.048	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: CENATAC tumor-vs-normal RNA expression · all CENATAC data types